MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Other Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Other current liabilities remains negative
Q3 FY2026 other current liabilities was $0, compared with $2.78M a year earlier. Over 3 fiscal years it compounded at +56.2% a year.
Context
- Other current liabilities amounted to 0.0% of total assets at the end of Q3 FY2026, down 0.7 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 4.32M USD
- Year-over-year change
- +85.9%
- 3-year CAGR
- +56.2%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.32M | +85.9% |
| FY2024 | 2024-12-31 | 2.32M | +70.3% |
| FY2023 | 2023-12-31 | 1.37M | +20.5% |
| FY2022 | 2022-12-31 | 1.13M | — |
Other Current Liabilities vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -100.0% is the lowest of 6, against a peer median of +64.8%.
- Other current liabilities amounts to 0.0% of total assets for MBX, versus a peer median of 2.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €365.32M EUR | -13.0% | +37.8% | 15.1% | |
| Mar 2026 | $100.86M USD | +211.5% | +54.4% | 25.7% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $82.6M USD | — | — | 6.8% |
| Sep 2026 | $14.75M USD | +64.8% | +67.5% | 3.3% | |
| Mar 2026 | $3.23M USD | +286.1% | — | 1.2% | |
| Mar 2026 | $159K USD | -39.1% | -35.7% | 0.3% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $0 USD | -100.0% | +56.2% | 0.0% |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding MBX) | — | +64.8% | +46.1% | 2.3% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.